Articles related to PTSD
Studies Illustrate Potential of MDMA-, Psilocybin-Assisted Therapies
A Phase 2B study found that a 25mg dose of psilocybin, combined with psychotherapy, produced a significant drop in patients’ scores on the Montgomery Asberg Depression Rating Scale (MADRS) after 12 weeks. This finding underscores the potential of psilocybin-assisted therapy as a promising treatment for depression.
Psychiatry November 7th 2023
Topiramate Monotherapy for Civilian Posttraumatic Stress Disorder: A Controlled Pilot Study
This double-blind, placebo-controlled trial suggests that topiramate monotherapy may be an effective treatment for civilian PTSD. Despite the decrease in total CAPS score not being statistically significant, topiramate-treated patients exhibited significant reductions in reexperiencing symptoms.
Psychiatry November 1st 2023
The Weekly Mind Reader: Topiramate’s Potential Role in PTSD Treatment
The recent study on topiramate’s potential role in PTSD treatment has shown that three times as many patients taking topiramate saw their PTSD symptoms decrease below the clinical threshold compared to those on placebo.
Psychiatry October 24th 2023
Antihypertensive Medications and PTSD Incidence in a Trauma Cohort
This 22-year study provides a detailed examination of the relationship between antihypertensive medications and PTSD incidence in trauma victims. Physicians interested in the potential preventive role of these medications in PTSD are invited to delve into the findings and implications for future research.
Neurology August 15th 2023